» Articles » PMID: 20646772

Epigenetic Regulation of Cancer Stem Cells in Liver Cancer: Current Concepts and Clinical Implications

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2010 Jul 22
PMID 20646772
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The two dominant models of carcinogenesis postulate stochastic (clonal evolution) or hierarchic organization of tumor (cancer stem cell model). According to the latter, at the germinal center of tumor evolution is a cancer stem cell (CSC) which, similar to normal adult stem cells, possesses the capacity of self-renewal and a differentiation potential. Over the past few years, compelling evidence has emerged in support of the hierarchic cancer model for many solid tumors including hepatocellular cancers. The CSCs are posited to be responsible not only for tumor initiation but also for the generation of distant metastasis and relapse after therapy. These characteristics are particularly relevant for a multi-resistant tumor entity like human hepatocellular carcinoma and may herald a paradigm shift in the management of this deadly disease. Identification and detailed characterization of liver CSCs is therefore imperative for improving prevention approaches, enhancing early detection, and extending the limited treatment options. Despite the current progress in understanding the contribution of CSCs to the generation of heterogeneity of tumors, the molecular complexity and exact regulation of CSCs is poorly understood. This review focuses on the genetic and epigenetic mechanisms that regulate and define the unique CSC properties with an emphasis on key regulatory pathways of liver CSCs and their clinical significance.

Citing Articles

Overview of hepatocarcinogenesis focusing on cellular origins of liver cancer stem cells: a narrative review.

Eun J J Yeungnam Med Sci. 2024; 42:3.

PMID: 39523770 PMC: 11812091. DOI: 10.12701/jyms.2024.01088.


Artificial and Natural Sweeteners Biased T1R2/T1R3 Taste Receptors Transactivate Glycosylated Receptors on Cancer Cells to Induce Epithelial-Mesenchymal Transition of Metastatic Phenotype.

Skapinker E, Aldbai R, Aucoin E, Clarke E, Clark M, Ghokasian D Nutrients. 2024; 16(12).

PMID: 38931195 PMC: 11206856. DOI: 10.3390/nu16121840.


Functional Selectivity of Cannabinoid Type 1 G Protein-Coupled Receptor Agonists in Transactivating Glycosylated Receptors on Cancer Cells to Induce Epithelial-Mesenchymal Transition Metastatic Phenotype.

Bunsick D, Matsukubo J, Aldbai R, Baghaie L, Szewczuk M Cells. 2024; 13(6.

PMID: 38534324 PMC: 10969603. DOI: 10.3390/cells13060480.


TrkB inhibition of DJ-1 degradation promotes the growth and maintenance of cancer stem cell characteristics in hepatocellular carcinoma.

Kim M, Lee W, Jin W Cell Mol Life Sci. 2023; 80(10):303.

PMID: 37749450 PMC: 10520132. DOI: 10.1007/s00018-023-04960-z.


SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.

Wang S, You X, Liu X, Zhang F, Zhou H, Shang X iScience. 2023; 26(7):106994.

PMID: 37534166 PMC: 10391607. DOI: 10.1016/j.isci.2023.106994.


References
1.
Gilbert C, Ross A . Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem. 2009; 108(5):1031-8. PMC: 2909872. DOI: 10.1002/jcb.22350. View

2.
Segal E, Friedman N, Koller D, Regev A . A module map showing conditional activity of expression modules in cancer. Nat Genet. 2004; 36(10):1090-8. DOI: 10.1038/ng1434. View

3.
Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

4.
Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

5.
Valk-Lingbeek M, Bruggeman S, van Lohuizen M . Stem cells and cancer; the polycomb connection. Cell. 2004; 118(4):409-18. DOI: 10.1016/j.cell.2004.08.005. View